<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00350753</url>
  </required_header>
  <id_info>
    <org_study_id>EB-UGI-01</org_study_id>
    <secondary_id>2006-001308-35</secondary_id>
    <nct_id>NCT00350753</nct_id>
  </id_info>
  <brief_title>Avastin and Tarceva for Upper Gastrointestinal Cancers</brief_title>
  <official_title>A Phase II Study of Erlotinib and Bevacizumab in Patients With Advanced Upper Gastrointestinal Carcinomas, Refractory or Intolerable to Standard Systemic Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <brief_summary>
    <textblock>
      Erlotinib and bevacizumab have shown activity individually, as single drugs, or in&#xD;
      combination with chemotherapy in upper gastro-intestinal cancers, including esophageal and&#xD;
      gastro-esophageal adenocarcinomas, gastric cancer and pancreatic cancer. Biomarkers&#xD;
      indicating an important role of EGF and VEGF have been found in these tumors, and in&#xD;
      cholangiocarcinomas as well. There is promise that combined treatment with erlotinib and&#xD;
      bevacizumab is active and tolerable in a broad range of upper gastro-intestinal cancers,&#xD;
      justifying an experimental phase II-study of patients with these diagnoses, refractory or&#xD;
      intolerant to standard systemic therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective&#xD;
&#xD;
        -  To determine the median time to progression (TTP) and response rate (RR) of the&#xD;
           combination of erlotinib and bevacizumab in patients with advanced upper&#xD;
           gastro-intestinal carcinomas, refractory or intolerant to standard systemic therapy.&#xD;
&#xD;
      Secondary Objective&#xD;
&#xD;
        -  To determine safety, tolerability and toxicity.&#xD;
&#xD;
        -  To determine median and overall survival (OS).&#xD;
&#xD;
        -  To correlate efficacy of treatment with the expression of tumor markers obtained in&#xD;
           serum (EFGR, bFGF, p-VEGF-A, and sVEGF-R2), in paraffin embedded tumor tissue (micro&#xD;
           vessel density (MVD), and expression of VEGFR and EGFR, after immunostaining), and in&#xD;
           fresh frozen tumor biopsies (micro array-based analyses of patterns of gene expression).&#xD;
&#xD;
      Treatment:&#xD;
&#xD;
      Bevacizumab (AvastinÒ) will be given intravenously at 10 mg/kg every other week.&#xD;
&#xD;
      Erlotinib is given as an orally daily dose and most be taken at least one hour before or two&#xD;
      hours after ingestion of food.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response by RECIST criteria</measure>
    <time_frame>From time of treatment start to response evaluation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to progression</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity evaluated by NCI-CTCae version 3.0</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Cholangiocarcinoma</condition>
  <condition>Gallbladder Cancer</condition>
  <arm_group>
    <arm_group_label>Erlotinib and bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib and bevacizumab</intervention_name>
    <description>Erlotonib 150 mg daily bevacizumab 10 mg/kg every 14 days</description>
    <arm_group_label>Erlotinib and bevacizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically verified carcinoma of the gall bladder or bile ducts.&#xD;
&#xD;
          -  PS 0-1 (ECOG scale)&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  Sufficient organ function, defined as:&#xD;
&#xD;
               -  Platelets &gt; 100 x 109/liter&#xD;
&#xD;
               -  Leukocytes &gt; 3,0 x 109/liter&#xD;
&#xD;
               -  ACN &gt; 1,5 x 109/liter&#xD;
&#xD;
               -  ASAT and/or ALAT &lt; 3 x upper normal limit&#xD;
&#xD;
               -  Bilirubin &lt; 1,5 x upper normal limit&#xD;
&#xD;
               -  EDTA clearance &gt; 45 ml/min&#xD;
&#xD;
               -  APTT and INR &lt; normal limit&#xD;
&#xD;
          -  Fertile females must use oral contraceptive, IUD (intrauterine device) or&#xD;
             preservatives. Fertile males must use preservatives.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Radiotherapy or chemotherapy within the last 4 weeks&#xD;
&#xD;
          -  Co-medication that may interfere with study results; e.g. immuno-suppressive agents&#xD;
             other than corticosteroids&#xD;
&#xD;
          -  Any prior EGFR- or VEGFR-based therapy&#xD;
&#xD;
          -  Any condition (medical, social, psychological), which would prevent adequate&#xD;
             information and follow-up&#xD;
&#xD;
          -  Tumor located close to major blood vessels and judged to possess a high risk of&#xD;
             serious bleeding&#xD;
&#xD;
          -  Any other active malignancy, except basal or squamous cell carcinoma of the skin, or&#xD;
             carcinoma in situ&#xD;
&#xD;
          -  Any significant cardiac disease (New York Heart Association Class II or greater),&#xD;
             significant arrythmia, congestive heart failure, acute myocardial infarction within 6&#xD;
             months or unstable angina pectoris&#xD;
&#xD;
          -  Clinically significant peripheral vascular disease&#xD;
&#xD;
          -  Evidence of coagulopathy&#xD;
&#xD;
          -  Use of ASA, NSAIDs or clopidogrel&#xD;
&#xD;
          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days&#xD;
             prior to treatment, anticipation of need for major surgical procedure during the curse&#xD;
             of the study&#xD;
&#xD;
             o Minor surgical procedures, fine needle aspirations or core biopsies within 7 days&#xD;
             prior to treatment&#xD;
&#xD;
          -  History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess&#xD;
             within 6 month prior to treatment&#xD;
&#xD;
          -  Any ongoing infection, uncontrolled diabetes mellitus, serious non-healing wound or&#xD;
             ulcer&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Ongoing therapeutic anti-coagulation&#xD;
&#xD;
          -  Hypertension with blood pressure &gt; 150/100 mmHg&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulrik Lassen, MD., PH.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Dept. of Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Århus Sygehus</name>
      <address>
        <city>Århus</city>
        <zip>8000 C</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <study_first_submitted>July 10, 2006</study_first_submitted>
  <study_first_submitted_qc>July 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2006</study_first_posted>
  <last_update_submitted>July 14, 2009</last_update_submitted>
  <last_update_submitted_qc>July 14, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 15, 2009</last_update_posted>
  <responsible_party>
    <name_title>Ulrik Lassen</name_title>
    <organization>Rigshospitalet</organization>
  </responsible_party>
  <keyword>Cholangiocarcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Gallbladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

